医学临床研究
  2025年4月5日 星期六           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2022, Vol. 39 Issue (3): 374-377    DOI: 10.3969/j.issn.1671-7171.2022.03.015
  论著 本期目录 | 过刊浏览 | 高级检索 |
右旋布洛芬治疗幼年特发性关节炎患儿的疗效观察
赵苗苗, 张昆*
汉中市中心医院儿科,陕西 汉中 723000
Efficacy and Safety of Dexibuprofen in Children with Juvenile Idiopathic Arthritis
ZHAO Miao-miao, ZHANG Kun
Department of Pediatrics Hanzhong Central Hospital, Hanzhong Shaanxi 723000
全文: PDF (1131 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 【目的】探讨右旋布洛芬治疗幼年特发性关节炎(JIA)患儿的疗效、安全性及对血清中致痛介质、炎症因子表达的影响。【方法】在本院就诊的JIA患儿84例,随机分为对照组和观察组,每组各42例。 对照组给予萘普生治疗,观察组给予右旋布洛芬治疗,均持续治疗2周。对比两组临床疗效,采用幼年关节炎疾病活动性评分表(JADAS27)评定患儿治疗前后临床症状及体征改善情况,并分析治疗前后血清中致痛介质[5-羟色胺(5-HT)、前列腺素E2(PGE2)、缓激肽(BK)、神经肽Y(NPY)]及炎症因子[肿瘤坏死因子-α(TNF-α)、白介素1(IL-1)、白介素17(IL-17)、基质金属蛋白酶-3(MMP-3)]表达水平的变化,比较两组不良反应发生率。【结果】观察组患儿治疗总有效率为85.71%(36/42),显著高于对照组的64.29%(27/42)(P<0.05)。两组患儿治疗后JADAS27各维度评分及总分均显著低于治疗前(均P<0.05),且观察组治疗后上述指标均显著低于对照组(均P<0.05)。两组患儿治疗后血清5-HT、PGE2、BK、NPY及TNF-α、IL-1、IL-17、MMP-3水平均显著低于治疗前(均P<0.05),且观察组患儿治疗后上述指标均显著低于对照组(均P<0.05)。观察组患儿不良反应发生率为4.76%(2/42),显著低于对照组的19.05%(8/42)(P<0.05)。【结论】右旋布洛芬治疗JIA疗效显著,能够明显改善患儿的临床症状及体征,抑制炎症因子和致痛介质的表达,且安全性较好。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
赵苗苗
张昆
关键词 关节炎, 青少年布洛芬/治疗应用治疗结果    
Abstract:【Objective】To investigate the efficacy and safety of dexibuprofen in children with juvenile idiopathic arthritis (JIA) and the expression of serum pain mediators and inflammatory factors. 【Methods】A total of 84 patients with JRA in our hospital were selected as the research objects and they were randomly divided into two groups, with 42 cases in the control group and 42 cases in the observation group. The control group was treated with naproxen, while the study group was treated with dexibuprofen for 2 weeks. The juvenile arthritis disease activity scale (JADAS27) was used to assess the improvement of clinical symptoms and physical signs before and after treatment. The serum pain mediators [serotonin (5-HT) and prostaglandin E2 (PGE2), slow excitation peptide bradykinin (BK), neuropeptide Y (NPY)] and inflammatory factor [tumor necrosis factor alpha (TNF-α), interleukin 1 (IL-1), interleukin 17 (IL-17), matrix metalloproteinases-3(MMP-3)] expression levels were compared between the two groups as well. The incidence of adverse reactions were also compared. 【Results】The total effective rate of the observation group was 85.71%, which was significantly higher than 64.29% of the control group (P<0.05). The scores of each dimension and total score of JADAS27 in the two groups after treatment were significantly lower than those before treatment (all P<0.05), and the above indexes in the observation group after treatment were significantly lower than those in the control group after treatment (all P<0.05). The serum levels of 5-HT, PGE2, BK, NPY, TNF-α, IL-1, IL-17 and MMP-3 in the two groups after treatment were significantly lower than those before treatment (all P<0.05), and the above indexes in the observation group were significantly lower than those in the control group (all P<0.05). The incidence of adverse reactions in the observation group was 4.76% (2/42), which was significantly lower than 19.05% (8/42) in the control group (P<0.05). 【Conclusion】The efficacy of dextral ibuprofen (dexibuprofen) in the treatment of JIA is remarkable, which can significantly improve the clinical symptoms and signs of children, inhibit the expression of inflammatory factors and pain-causing mediators, and has good safety.
Key wordsArthritis, Juvenile    Ibuprofen/TU    Treatment Outcome
收稿日期: 2021-06-17     
中图分类号:  R452  
通讯作者: * E-mail:3458622@qq.com   
引用本文:   
赵苗苗, 张昆. 右旋布洛芬治疗幼年特发性关节炎患儿的疗效观察[J]. 医学临床研究, 2022, 39(3): 374-377.
ZHAO Miao-miao, ZHANG Kun. Efficacy and Safety of Dexibuprofen in Children with Juvenile Idiopathic Arthritis. JOURNAL OF CLINICAL RESEARCH, 2022, 39(3): 374-377.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2022.03.015     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2022/V39/I3/374
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn